|
A single-arm multicenter phase II trial of doxorubicin (Doxo) in combination with trabectedin (Trab) given as first-line treatment to patients with metastatic/advanced uterine (U-LMS) and soft tissue leiomyosarcoma (ST-LMS): Final results of the LMS-02 study. |
|
|
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Roche; Tesaro |
Travel, Accommodations, Expenses - GlaxoSmithKline; Roche; Tesaro |
|
|
Consulting or Advisory Role - AstraZeneca; CLOVIS ONCOLOGY; GlaxoSmithKline; MSD Oncology; Roche; Tesaro |
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; GlaxoSmithKline; MSD Oncology; Roche; Tesaro |
|
|
No Relationships to Disclose |
|
|
Research Funding - Bayer (Inst); Bayer (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; Astellas Pharma; Janssen-Cilag |
Other Relationship - PharmaMar |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Pascaline Boudou-Rouquette |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer; Lilly; PharmaMar |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer Health |
Travel, Accommodations, Expenses - Leo Pharma; PharmaMar |